GlassScriptPhysician profile
Jeffrey David Wartman
NPI 1295730414
$5,769.54
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $798 · 2021: $1,212 · 2022: $887 · 2023: $1,069 · 2024: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.91 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.20 | 2019-2024 | Qulipta, Vraylar, Ubrelvy |
| Lilly USA, LLC | $440.64 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $433.58 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals LP | $427.21 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $348.96 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.26 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $266.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.49 | 2021-2024 | |
| Amarin Pharma, INC. | $250.58 | 2019-2021 | |
| Astellas Pharma US INC | $214.77 | 2019-2024 | Veozah |
| Pfizer INC. | $206.34 | 2019-2024 | |
| Abbott Laboratories | $189.58 | 2019-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $187.33 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $150.52 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceuticals, INC. | $145.36 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.